Hits, leads and drugs against malaria through diversity-oriented synthesis. (December 2012)

• Record Type: Journal Article
• Authors: Dandapani, Sivaraman; Comer, Eamon; Duvall, Jeremy R; Munoz, Benito
• Is Part Of: Future medicinal chemistry. Volume 4:Number 18(2012)
• Page Start: 2279
• Page End: 2294
• Publication Date: 2012-12
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc.12.178
• Languages: English
• ISSNs: 1756-8919

Abstract

Malaria is a devastating infectious disease and approximately half the world's population is at risk. Since vaccination is not yet available, small-molecule-based medicines are currently the best option for the treatment of patients suffering from malaria and combating the spread of infection. Development of resistance against existing drugs has created a need for new types of small molecules to be screened against Plasmodium falciparum, the etiological agent of malaria. The advent of diversity-oriented synthesis has enabled access to novel chemical structures. Evaluation of diversity-oriented synthesis compounds in phenotypic assays for growth inhibition of P. falciparum has resulted in novel hits, leads and even investigational drugs against malaria.